MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
6. Technology Transfer (T2), NonDilutive Funding: Strategy Development
* T2ToolBox
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
Eisai Co., Ltd
Organization & Developments: Eisai
Parents
Eisai Co., Ltd
Children
2007: Integrated pharmaceutical company with $2 billion in sales (2007)
2014: Biogen, Eisai Join Up in Alzheimer’s Drug Pact
2016: Arena: Belviq Sales Still Slow - Will Eisai Stick Around? - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
2022: Eisai and Biogen's phase 3 Alzheimer's win puts amyloid back in the driver's seat, for now
2023: FDA grants full approval to new Alzheimer's drug meant to slow disease
2023: Japanese pharma Eisai forms digital dementia support biz
2023: With Leqembi approval in Alzheimer's disease, Eisai and Biogen plot 'meticulous' launch
2024: Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
2025: FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
2025: Merck, Eisai combo meets key goal in advanced kidney cancer trial (MRK:NYSE) | Seeking Alpha
5 Stone Cliff Terrace
H3 Biomedicine
Japanese pharmaceutical titan
Jumps
*Key People: Eisai
Finance & Acquisitions: Eisai